Pipeline – CarthroniX – Innovative solutions in regenerative therapeutics

Pipeline and Key Milestones

Our primary focus is advancing our lead candidate, CX-011, into clinical trials for osteoarthritis. We are also leveraging our inflammation-modulating technology across multiple conditions, including fibrotic diseases and immuno-oncology. Our pipeline is designed to create value by hitting key clinical and regulatory milestones.

Upcoming Milestones

Q4 2025: Planned start of Phase 1/2A clinical trial of CX-011 in knee osteoarthritis patients.

Recent Achievements

Apr 2025: Closed $1.25M financing from Pacira BioSciences to fund the Phase 1/2a clinical trial of CX-011.
Mar 2025: Received clearance from the FDA to initiate first-in-human clinical study of CX-011.
Jan 2023: Awarded a $5.0M U.S. Department of Defense grant to support CX-011 clinical development.
Sept 2022: Received NIH SBIR grant to advance our fibrosis therapy program.
June 2022: Formed partnership with Boehringer Ingelheim (animal health) to develop small-molecule therapies in canine oncology.
Apr 2022: Closed $2.25M financing (led by Pacira BioSciences) to finalize pre-clinical development of CX-011.